- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01976923
Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy
Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy: Results of the Pan-American Collaborative Retina Study (PACORES) Group
Study Overview
Status
Intervention / Treatment
Detailed Description
This will be a prospective, randomized, active-controlled study of 224 eyes of patients with the diagnosis of TRD secondary to PDR. Participants will be screened for eligibility. Eligible patients will be examined at baseline to determine their ocular condition and randomized into 2 arms. Patients will be randomized in a 1:1 ratio to the study arm.
- Control arm: PPV without pre-operative bevacizumab (Sham injection).
- Study arm: Pre-operative bevacizumab (3-5 days) before PPV.
In the study arm, an intravitreal bevacizumab injection at a dose of 1.25 µg/0.05 mL will be scheduled 3 to 5 days before minimally invasive vitreoretinal surgery (MIVS).
The purpose of the current study is to determine the effectiveness and safety of an intravitreal injection of 1.25 mg of bevacizumab as a pre-operative adjunct to PPV in eyes with TRD secondary to PDR.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Riyadh, Saudi Arabia, 11462
- King Khaled Eye Specialist Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age >= 18 years with proliferative diabetic retinopathy (PDR) and tractional retinal detachment (TRD) threatening or involving the fovea.
- Diagnosis of diabetes mellitus (type 1 or type 2)
- At least one eye meets the study eye criteria
- One eye per patient will be included
- Able and willing to provide informed consent prior to any study-related procedures
- Best corrected visual acuity 20/40 or less
- Willing and able to comply with clinic visits and study-related procedures
- U.S. patients will be required to have a Health Insurance Portability and Accountability Act (HIPAA) authorization; in other countries, as applicable according to national laws
Exclusion Criteria:
Ocular Exclusion Criteria
The following exclusions apply to the study eye only (i.e., they may be present for the non-study eye):
- TRD is considered to be due to a cause other than diabetes.
- An ocular condition is present such that, in the opinion of the investigator, visual acuity loss would not improve from resolution of TRD (e.g., foveal atrophy, pigment abnormalities, dense subfoveal hard exudates, nonretinal condition, optic atrophy).
- An ocular condition is present (other than diabetes) that, in the opinion of the investigator, might affect retinal status or alter visual acuity during the course of the study (e.g., retinal vein occlusion, uveitis or other ocular inflammatory disease, glaucoma, etc.)
- History of treatment for diabetic macular edema or diabetic retinopathy at any time in the past 4 months with anti-vascular endothelial growth factor (VEGF) drugs.
- History of major ocular surgery (including vitrectomy, cataract extraction, scleral buckle, any intraocular surgery, etc.) within prior 4 months of randomization.
- History of neodymium-doped yttrium aluminium garnet (YAG) capsulotomy performed within 2 months prior to randomization.
- Intraocular pressure >= 25 mmHg.
- Exam evidence of external ocular infection, including conjunctivitis, chalazion, or significant blepharitis
- An ocular condition is present (other than diabetes) that, in the opinion of the investigator, might affect retinal status or including hypertension, cardiovascular disease, and glycemic control.
Systemic Exclusion Criteria
A participant is not eligible if any of the following exclusion criteria are present:
- Significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant.
- A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including hypertension, cardiovascular disease, and glycemic control).
- Participation in an investigational trial within 30 days of randomization that involved treatment with any drug that has not received regulatory approval at the time of study entry.
- Known allergy to any component of the study drug.
- Blood pressure > 180/110 mmHg (systolic above 180 or diastolic above 110).
- Major surgery within 28 days prior to randomization or major surgery planned during the next 6 months.
- Myocardial infarction, other cardiac event requiring hospitalization, stroke, transient ischemic attack, or treatment for acute congestive heart failure within 4 months prior to randomization.
- Systemic anti-VEGF or VEGF treatment within 4 months prior to randomization.
- For women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 12 months.
- Participant is expecting to move out of the area of the clinical center to an area not covered by another clinical center during the first 12 months of the study.
- Participation in an investigational trial within 30 days of randomization that involved treatment with any drug that has not received regulatory approval at the time of study entry.
- Known allergy to any component of the study drug.
- Blood pressure > 180/110 mmHg (systolic above 180 or diastolic above 110).
- Major surgery within 28 days prior to randomization or major surgery planned during the next 6 months.
- Myocardial infarction, other cardiac event requiring hospitalization, stroke, transient ischemic attack, or treatment for acute congestive heart failure within 4 months prior to randomization.
- Systemic anti-VEGF or VEGF treatment within 4 months prior to randomization.
- For women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 12 months.
- Participant is expecting to move out of the area of the clinical center to an area not covered by another clinical center during the first 12 months of the study.
- History of blood diseases associated with abnormal coagulation.
- Anti-coagulant therapy (warfarin or heparin).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Study arm
Intravitreal bevacizumab Small-gauge pars plana vitrectomy
|
A sterile lid speculum is used to separate the lids.
A subconjunctival injection of 1% lidocaine is applied to the inferotemporal quadrant.
A 5% povidone iodine solution is used to disinfect the entire conjunctival surface.
1.25 mg / 0.05 mL of bevacizumab is injected using a 30-gauge needle inserted through the inferotemporal pars plana 3.5 mm from the limbus.
|
Sham Comparator: Control arm
Small-gauge pars plana vitrectomy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intraoperative bleeding
Time Frame: 12 months
|
12 months
|
|
Total surgical time
Time Frame: 12 months
|
12 months
|
|
Post-operative vitreous hemorrhage
Time Frame: 12 months
|
Early (<1 month) and late (≥ 1 month) post-operative vitreous hemorrhage (VH) (Yes or No)
|
12 months
|
Visual acuity change
Time Frame: 12 months
|
Mean change in best-corrected visual acuity (BCVA) at 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of endodiathermy applications
Time Frame: 12 months
|
12 months
|
Intraoperative breaks
Time Frame: 12 months
|
12 months
|
Change in central macular thickness
Time Frame: 12 months
|
12 months
|
Proportion of eyes gaining at least 15 letters of BCVA
Time Frame: 12 months
|
12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Molecules in the vitreous humor and epiretinal membranes
Time Frame: 12 months
|
We would now like to examine molecules in the vitreous humor and epiretinal membranes to gain insight and better assess the efficacy and outcomes of pre-operative intravitreal bevacizumab.
|
12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Arevalo JF, Sanchez JG, Lasave AF, Wu L, Maia M, Bonafonte S, Brito M, Alezzandrini AA, Restrepo N, Berrocal MH, Saravia M, Farah ME, Fromow-Guerra J, Morales-Canton V. Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture. J Ophthalmol. 2011;2011:584238. doi: 10.1155/2011/584238. Epub 2011 Mar 30.
- Arevalo JF, Sanchez JG, Saldarriaga L, Berrocal MH, Fromow-Guerra J, Morales-Canton V, Wu L, Maia M, Saravia MJ, Bareno J; Pan American Collaborative Retina Study Group. Retinal detachment after bevacizumab. Ophthalmology. 2011 Nov;118(11):2304.e3-7. doi: 10.1016/j.ophtha.2011.05.015. No abstract available.
- Arevalo JF, Garcia-Amaris RA. Intravitreal bevacizumab for diabetic retinopathy. Curr Diabetes Rev. 2009 Feb;5(1):39-46. doi: 10.2174/157339909787314121.
- Arevalo JF, Maia M, Flynn HW Jr, Saravia M, Avery RL, Wu L, Eid Farah M, Pieramici DJ, Berrocal MH, Sanchez JG. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008 Feb;92(2):213-6. doi: 10.1136/bjo.2007.127142. Epub 2007 Oct 26.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Neoplasms
- Eye Diseases
- Endocrine System Diseases
- Diabetic Angiopathies
- Diabetes Complications
- Diabetes Mellitus
- Neoplastic Processes
- Retinal Diseases
- Diabetic Retinopathy
- Neoplasm Metastasis
- Retinal Detachment
- Dissociative Disorders
- Physiological Effects of Drugs
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Bevacizumab
Other Study ID Numbers
- 1338-P
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy
-
Ruijin HospitalCompletedProliferative Diabetic Retinopathy | Tractional Retinal DetachmentChina
-
Khairallah MoncefRecruitingProliferative Diabetic Retinopathy | Vitreous Hemorrhage | Tractional Retinal DetachmentTunisia
-
Nihon UniversityCompletedProliferative Diabetic Retinopathy | Vitreous Hemorrhage | Diabetic Traction Retinal DetachmentJapan
-
Iran University of Medical SciencesCompletedDiabetic Retinopathy | Pars Plana Vitrectomy | Intravitreal Bevacizumab Injection | Tractional Retinal DetachmentIran, Islamic Republic of
-
Mid Atlantic RetinaCompletedDiabetic Retinopathy | Retinal Detachment | Vitrectomy | Proliferative VitreoretinopathyUnited States
-
Kasr El Aini HospitalCompletedTractional Retinal Detachment | Diabetic Vitreous HemorrhageEgypt
-
Greater Houston Retina ResearchWithdrawn
-
University of CataniaUnknownProliferative Diabetic Retinopathy | Non Proliferative Diabetic RetinopathyItaly
-
Asociación para Evitar la Ceguera en MéxicoUnknownProliferative Diabetic Retinopathy | Non Proliferative Diabetic RetinopathyMexico
-
Ocuphire Pharma, Inc.CompletedDiabetic Retinopathy | Diabetic Macular Edema | NPDR - Non Proliferative Diabetic Retinopathy | PDR - Proliferative Diabetic RetinopathyUnited States
Clinical Trials on Intravitreal bevacizumab
-
University of Campania "Luigi Vanvitelli"Completed
-
Shahid Beheshti University of Medical SciencesActive, not recruitingDiabetic Macular EdemaIran, Islamic Republic of
-
Shahid Beheshti University of Medical SciencesUnknownRetinal Vein Occlusion With Macular EdemaIran, Islamic Republic of
-
Jaeb Center for Health ResearchNational Eye Institute (NEI); Genentech, Inc.; Regeneron PharmaceuticalsCompletedDiabetic Macular EdemaUnited States
-
Sivakami A PaiUnknownStage 2+ or Stage 3+ Retinopathy of Prematurity in Zone I or Zone II.United Arab Emirates
-
Instituto de Olhos de GoianiaUnknownAge Related Macular DegenerationBrazil
-
Cairo UniversityTerminatedDiabetic Retinopathy | Diabetic Macular Edema | Vascular Endothelial Growth Factor Overexpression | Macular IschemiaEgypt
-
Panhandle Eye Group, LLPCompletedDiabetic RetinopathyMexico
-
University of MalayaUnknownAge Related Macular DegenerationMalaysia
-
Barnes Retina InstituteMassachusetts Eye and Ear Infirmary; Long Island Vitreoretinal Consultants; Illinois... and other collaboratorsCompletedMacular Edema | Retinal Vein OcclusionUnited States